At Upstream Bio we strive to reach the source of inflammation and conquer it. We are leveraging our diverse roots and the team’s substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones.
Location: United States, Massachusetts, Waltham
Employees: 11-50
Total raised: $400M
Founded date: 2021
Investors 6
| Date | Name | Website |
| 28.06.2022 | Omega Fund... | omegafunds... |
| - | Access Bio... | accessbio-... |
| 06.06.2022 | OrbiMed | orbimed.co... |
| - | TCG Crosso... | tcgcrossov... |
| 26.08.2022 | HBM Partne... | hbmpartner... |
| 04.10.2024 | Bain Capit... | baincapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 08.06.2023 | Series B | $200M | - |
| 12.06.2022 | Series A | $200M | OrbiMed |
Mentions in press and media 8
| Date | Title | Description |
| 12.08.2026 | Agritech and Foodtech Surge: AI and Biotech Redefine Global Food Systems | Agritech and foodtech markets are booming. Significant capital infuses AI, biotech, and sustainable solutions across the global food system. Ambrook closed a $30M Series B for farm financial management software, reaching 8,000 customers. Pl... |
| 06.08.2026 | AgriFood Signals: Eatable Adventures launches accelerator, Ambrook raises $30m, LIVEKINDLY acquires Dalco | AgFunderNews rounds up the most important fundings, mergers, acquisitions, closures, and industry buzz in agtech and foodtech. Funding news 🇺🇸 Plantible raises $35m in debt, equity, to increase RuBisCO protein production fivefold AgFunderNe... |
| 15.10.2024 | Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares | WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announc... |
| 14.10.2024 | HBM portfolio company Upstream Bio raises USD 255 million in successful initial public offering | Upstream Bio (Nasdaq: UPB), a previously private company in the HBM Healthcare Investments portfolio, got off to a successful start on the stock market last Friday. The company raised USD 255 million in new capital through the issuance of 1... |
| 08.06.2023 | Upstream Bio Announces $200M Series B Financing | - |
| 02.06.2022 | Upstream Bio Launches with $200M Series A | - |
| 02.06.2022 | Upstream Bio Raises $200M in Series A Financing | Upstream Bio, a Waltham, Mass.-based biotech company focused on inflammation, raised $200 million in Series A financing. The Series A round was led jointly by OrbiMed and Maruho Co., Ltd. with participation from Access Biotechnology, Dechen... |
| - | Upstream Bio | “At Upstream Bio we strive to reach the source of inflammation and conquer it. We are leveraging our diverse roots and the team’s substantial industry experience to develop therapies that ease the burden of inflammatory and allergic disease... |